Abstract 1181P
Background
NeuroEndocrine Neoplasms (NENs) are rare tumors and can grow in almost all tissues. Regardlesshistological, molecular and imaging characteristicsthat are indicative of the primary origin, significant percentage remains of unknown primary.
Methods
A prospective observational study was conducted by HeSMO in Oncology Departments to register patients with histologically confirmed NEN. Inclusion criteria were: a) residencyin Greece, b) treatment by medical Oncologist in Greece, c) Age > 14 years and d) signed informed consent.
Results
223 patients (pts) diagnosed with NENs were enrolled of 7 centers from 1/2012to 2/2020.The female to maleratio (104/119) was 1.1 and the age range was 19-89 years (ys). The higher incidence concerned the age range 60-69 ys (27.8% 62 pts), followed by 70-79 ys (21.97% 49 pts) and 50-59 ys (21.5% 48 pts). The most frequently primary sites were lung (26.9% 60 pts), pancreas (15.69% 35 pts) and stomach (12.1% 27 pts). Less frequent were ileum/small intestine (5.38% 12 pts), cecum (4.93% 11 pts), colon (3.58% 8 pts), duodenum (2.24% 4 pts) and rectum (1.79% 3 pts). Less common primary sites were in 15.24% (34 pts) whereas in12.10% (27 pts) they were unknown primary tumors. The distribution of stages at diagnosis, were early stage in 20%, locally advanced in 48% and metastatic in 32%pts. Results regarding histology and treatments will be presented as well.
Conclusions
These are preliminary results from the largest prospective NEN registries in Greece. Due to the increased training of NEN specialists in pathologyand the improved imaging methods, NENs are increasingly recognized. However, a large percentage of pts are diagnosed in locally advanced or metastatic stages. It is necessaryto improve the rates of early diagnosis and identification of NENs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hellenic Society of Medical Oncology (HeSMO), Athens, Greece.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.